Global Neuromyelitis Optica Drug Market by Manufacturers, Regions, Type and Application, Forecast to 2021

According to Custom Market Inights analysis, The global neuromyelitis optica drug market is expected to register a healthy CAGR during the period from 2016 to 2025. This report studies the neuromyelitis optica drug status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the neuromyelitis optica drug by product type and applications/end industries.

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren’t yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

Scope of the Report:

This report focuses on the Neuromyelitis Optica Drug in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers

Pfizer

FRESENIUS

TEVA

SANDOZ

Intas

Gyjtrs

NANG KUANG

Tianjin Kingyork

Baxter

CSL

Grifols

Octapharma

CBOP

Market Segment by Regions, regional analysis covers

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America, Middle East and Africa

Market Segment by Type, covers

Production Market Share

Price Rage

Cost

Market Segment by Applications, can be divided into

Acute attack

Remission prophylactic treatment

There are 13 Chapters to deeply display the global Neuromyelitis Optica Drug market.

Chapter 1, to describe Neuromyelitis Optica Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Neuromyelitis Optica Drug, with sales, revenue, and price of Neuromyelitis Optica Drug, in 2015 and 2016;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Neuromyelitis Optica Drug, for each region, from 2011 to 2016;

Chapter 5, 6, 7 and 8, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 9 and 10, to show the market by type and application, with sales market share and growth rate by type, application, from 2011 to 2016;

Chapter 11, Neuromyelitis Optica Drug market forecast, by regions, type and application, with sales and revenue, from 2016 to 2021;

Chapter 12 and 13, to describe Neuromyelitis Optica Drug sales channel, distributors, traders, dealers, appendix and data source.

Table of Contents

Global Neuromyelitis Optica Drug Market by Manufacturers, Regions, Type and Application, Forecast to 2021

1 Market Overview

1.1 Neuromyelitis Optica Drug Introduction

1.2 Market Analysis by Type

1.2.1 Production Market Share

1.2.2 Price Rage

1.2.3 Cost

1.3 Market Analysis by Applications

1.3.1 Acute attack

1.3.2 Remission prophylactic treatment

1.3.3

1.4 Market Analysis by Regions

1.4.1 North America (USA, Canada and Mexico)

1.4.1.1 USA

1.4.1.2 Canada

1.4.1.3 Mexico

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany

1.4.2.2 France

1.4.2.3 UK

1.4.2.4 Russia

1.4.2.5 Italy

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China

1.4.3.2 Japan

1.4.3.3 Korea

1.4.3.4 India

1.4.3.5 Southeast Asia

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil

1.4.4.2 Egypt

1.4.4.3 Saudi Arabia

1.4.4.4 South Africa

1.4.4.5 Nigeria

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Pfizer

2.1.1 Business Overview

2.1.2 Neuromyelitis Optica Drug Type and Applications

2.1.2.1 Type 1

2.1.2.2 Type 2

2.1.3 Pfizer Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

2.2 FRESENIUS

2.2.1 Business Overview

2.2.2 Neuromyelitis Optica Drug Type and Applications

2.2.2.1 Type 1

2.2.2.2 Type 2

2.2.3 FRESENIUS Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

2.3 TEVA

2.3.1 Business Overview

2.3.2 Neuromyelitis Optica Drug Type and Applications

2.3.2.1 Type 1

2.3.2.2 Type 2

2.3.3 TEVA Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

2.4 SANDOZ

2.4.1 Business Overview

2.4.2 Neuromyelitis Optica Drug Type and Applications

2.4.2.1 Type 1

2.4.2.2 Type 2

2.4.3 SANDOZ Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

2.5 Intas

2.5.1 Business Overview

2.5.2 Neuromyelitis Optica Drug Type and Applications

2.5.2.1 Type 1

2.5.2.2 Type 2

2.5.3 Intas Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

2.6 Gyjtrs

2.6.1 Business Overview

2.6.2 Neuromyelitis Optica Drug Type and Applications

2.6.2.1 Type 1

2.6.2.2 Type 2

2.6.3 Gyjtrs Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

2.7 NANG KUANG

2.7.1 Business Overview

2.7.2 Neuromyelitis Optica Drug Type and Applications

2.7.2.1 Type 1

2.7.2.2 Type 2

2.7.3 NANG KUANG Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

2.8 Tianjin Kingyork

2.8.1 Business Overview

2.8.2 Neuromyelitis Optica Drug Type and Applications

2.8.2.1 Type 1

2.8.2.2 Type 2

2.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

2.9 Baxter

2.9.1 Business Overview

2.9.2 Neuromyelitis Optica Drug Type and Applications

2.9.2.1 Type 1

2.9.2.2 Type 2

2.9.3 Baxter Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

2.10 CSL

2.10.1 Business Overview

2.10.2 Neuromyelitis Optica Drug Type and Applications

2.10.2.1 Type 1

2.10.2.2 Type 2

2.10.3 CSL Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

2.11 Grifols

2.11.1 Business Overview

2.11.2 Neuromyelitis Optica Drug Type and Applications

2.11.2.1 Type 1

2.11.2.2 Type 2

2.11.3 Grifols Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

2.12 Octapharma

2.12.1 Business Overview

2.12.2 Neuromyelitis Optica Drug Type and Applications

2.12.2.1 Type 1

2.12.2.2 Type 2

2.12.3 Octapharma Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

2.13 CBOP

2.13.1 Business Overview

2.13.2 Neuromyelitis Optica Drug Type and Applications

2.13.2.1 Type 1

2.13.2.2 Type 2

2.13.3 CBOP Neuromyelitis Optica Drug Sales, Price, Revenue, Gross Margin and Market Share

3 Global Neuromyelitis Optica Drug Market Competition, by Manufacturer

3.1 Global Neuromyelitis Optica Drug Sales and Market Share by Manufacturer

3.2 Global Neuromyelitis Optica Drug Revenue and Market Share by Manufacturer

3.3 Market Concentration Rate

3.3.1 Top 3 Neuromyelitis Optica Drug Manufacturer Market Share

3.3.2 Top 6 Neuromyelitis Optica Drug Manufacturer Market Share

3.4 Market Competition Trend

4 Global Neuromyelitis Optica Drug Market Analysis by Regions

4.1 Global Neuromyelitis Optica Drug Sales, Revenue and Market Share by Regions

4.1.1 Global Neuromyelitis Optica Drug Sales by Regions (2011-2016)

4.1.2 Global Neuromyelitis Optica Drug Revenue by Regions (2011-2016)

4.2 North America Neuromyelitis Optica Drug Sales and Growth (2011-2016)

4.3 Europe Neuromyelitis Optica Drug Sales and Growth (2011-2016)

4.4 Asia-Pacific Neuromyelitis Optica Drug Sales and Growth (2011-2016)

4.5 South America Neuromyelitis Optica Drug Sales and Growth (2011-2016)

4.6 Middle East and Africa Neuromyelitis Optica Drug Sales and Growth (2011-2016)

5 North America Neuromyelitis Optica Drug by Countries

5.1 North America Neuromyelitis Optica Drug Sales, Revenue and Market Share by Countries

5.1.1 North America Neuromyelitis Optica Drug Sales by Countries (2011-2016)

5.1.2 North America Neuromyelitis Optica Drug Revenue by Countries (2011-2016)

5.2 USA Neuromyelitis Optica Drug Sales and Growth (2011-2016)

5.3 Canada Neuromyelitis Optica Drug Sales and Growth (2011-2016)

5.4 Mexico Neuromyelitis Optica Drug Sales and Growth (2011-2016)

6 Europe Neuromyelitis Optica Drug by Countries

6.1 Europe Neuromyelitis Optica Drug Sales, Revenue and Market Share by Countries

6.1.1 Europe Neuromyelitis Optica Drug Sales by Countries (2011-2016)

6.1.2 Europe Neuromyelitis Optica Drug Revenue by Countries (2011-2016)

6.2 Germany Neuromyelitis Optica Drug Sales and Growth (2011-2016)

6.3 UK Neuromyelitis Optica Drug Sales and Growth (2011-2016)

6.4 France Neuromyelitis Optica Drug Sales and Growth (2011-2016)

6.5 Russia Neuromyelitis Optica Drug Sales and Growth (2011-2016)

6.6 Italy Neuromyelitis Optica Drug Sales and Growth (2011-2016)

7 Asia-Pacific Neuromyelitis Optica Drug by Countries

7.1 Asia-Pacific Neuromyelitis Optica Drug Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Neuromyelitis Optica Drug Sales by Countries (2011-2016)

7.1.2 Asia-Pacific Neuromyelitis Optica Drug Revenue by Countries (2011-2016)

7.2 China Neuromyelitis Optica Drug Sales and Growth (2011-2016)

7.3 Japan Neuromyelitis Optica Drug Sales and Growth (2011-2016)

7.4 Korea Neuromyelitis Optica Drug Sales and Growth (2011-2016)

7.5 India Neuromyelitis Optica Drug Sales and Growth (2011-2016)

7.6 Southeast Asia Neuromyelitis Optica Drug Sales and Growth (2011-2016)

8 South America, Middle East and Africa Neuromyelitis Optica Drug by Countries

8.1 South America, Middle East and Africa Neuromyelitis Optica Drug Sales, Revenue and Market Share by Countries

8.1.1 South America, Middle East and Africa Neuromyelitis Optica Drug Sales by Countries (2011-2016)

8.1.2 South America, Middle East and Africa Neuromyelitis Optica Drug Revenue by Countries (2011-2016)

8.2 Brazil Neuromyelitis Optica Drug Sales and Growth (2011-2016)

8.3 Saudi Arabia Neuromyelitis Optica Drug Sales and Growth (2011-2016)

8.4 Egypt Neuromyelitis Optica Drug Sales and Growth (2011-2016)

8.5 Nigeria Neuromyelitis Optica Drug Sales and Growth (2011-2016)

8.6 South Africa Neuromyelitis Optica Drug Sales and Growth (2011-2016)

9 Neuromyelitis Optica Drug Market Segment by Type

9.1 Global Neuromyelitis Optica Drug Sales, Revenue and Market Share by Type (2011-2016)

9.1.1 Global Neuromyelitis Optica Drug Sales and Market Share by Type (2011-2016)

9.1.2 Global Neuromyelitis Optica Drug Revenue and Market Share by Type (2011-2016)

9.2 Production Market Share Sales Growth and Price

9.2.1 Global Production Market Share Sales Growth (2011-2016)

9.2.2 Global Production Market Share Price (2011-2016)

9.3 Price Rage Sales Growth and Price

9.3.1 Global Price Rage Sales Growth (2011-2016)

9.3.2 Global Price Rage Price (2011-2016)

9.4 Cost Sales Growth and Price

9.4.1 Global Cost Sales Growth (2011-2016)

9.4.2 Global Cost Price (2011-2016)

10 Neuromyelitis Optica Drug Market Segment by Application

10.1 Global Neuromyelitis Optica Drug Sales Market Share by Application (2011-2016)

10.2 Acute attack Sales Growth (2011-2016)

10.3 Remission prophylactic treatment Sales Growth (2011-2016)

10.4 Sales Growth (2011-2016)

10.5 Sales Growth (2011-2016)

11 Neuromyelitis Optica Drug Market Forecast (2016-2021)

11.1 Global Neuromyelitis Optica Drug Sales, Revenue and Growth Rate (2016-2021)

11.2 Neuromyelitis Optica Drug Market Forecast by Regions (2016-2021)

11.3 Neuromyelitis Optica Drug Market Forecast by Type (2016-2021)

11.4 Neuromyelitis Optica Drug Market Forecast by Application (2016-2021)

12 Sales Channel, Distributors, Traders and Dealers

12.1 Sales Channel

12.1.1 Direct Marketing

12.1.2 Indirect Marketing

12.1.3 Marketing Channel Future Trend

12.2 Distributors, Traders and Dealers

13 Appendix

13.1 Methodology

13.2 Analyst Introduction

13.3 Data Source

Name: (required)

Email: (required)

Phone: (required)

Company: (required)

Designation: (required)

Country: (required)

How can we help you?:

Type the pieces of text below (required)
captcha



Name: (required)

Email: (required)

Phone: (required)

Company: (required)

Designation: (required)

Country: (required)

How can we help you?:

Type the pieces of text below (required)
captcha



Jacob Thomass